Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73
Аутори
Đoković, JelenaMarković, Bojan
Sharmin, Dishary
Cook, James M.
Savić, Miroslav
Savić, Snežana
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Nanopharmaceuticals offer a good option to avoid
some of the difficulties that novel drug candidates
confront. They can be tailored to adjust their water
solubility, half-life, biodistribution, and govern the release
of the integrated medication. Because of the excipients
utilized, lipid nanocarriers (liposomes, nanoemulsions
(NEs), nanoparticles) have been used to increase brain
targeting (Bisso et al., 2020; Ilić et al., 2023).
The investigated compound (GL-II-73) - (4R)-8-
ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-
benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide is
imidazobenzodiazepine (IBZD) ligand that acts as positive
allosteric modulator on α-GABAA receptors and was
shown to possess combined antidepressant and pro-
cognitive effects, making it a promising candidate for
further research (Prevot et al., 2019).
This work aims to investigate the physicochemical
features of GL-II-73 to pick the best parenteral
nanodelivery system for prospective research to... assess its
parameters.
Кључне речи:
GL-II-73 / preformulation development / nanoemulsion stabilityИзвор:
Macedonian Pharmaceutical Bulletin, 2023, 69, Suppl 1, 53-54Издавач:
- Macedonian Pharmaceutical Association
- Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
Финансирање / пројекти:
- NanoCellEmoCog - Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platform (RS-ScienceFundRS-Ideje-7749108)
Напомена:
- 14th Central European Symposium on Pharmaceutical Technology, 28th - 30th September, Ohrid, N. Macedonia, 2023
- Poster: https://farfar.pharmacy.bg.ac.rs/handle/123456789/5049
Повезане информације:
- Повезани садржај
https://farfar.pharmacy.bg.ac.rs/handle/123456789/5049
Институција/група
PharmacyTY - CONF AU - Đoković, Jelena AU - Marković, Bojan AU - Sharmin, Dishary AU - Cook, James M. AU - Savić, Miroslav AU - Savić, Snežana PY - 2023 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5050 AB - Nanopharmaceuticals offer a good option to avoid some of the difficulties that novel drug candidates confront. They can be tailored to adjust their water solubility, half-life, biodistribution, and govern the release of the integrated medication. Because of the excipients utilized, lipid nanocarriers (liposomes, nanoemulsions (NEs), nanoparticles) have been used to increase brain targeting (Bisso et al., 2020; Ilić et al., 2023). The investigated compound (GL-II-73) - (4R)-8- ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H- benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide is imidazobenzodiazepine (IBZD) ligand that acts as positive allosteric modulator on α-GABAA receptors and was shown to possess combined antidepressant and pro- cognitive effects, making it a promising candidate for further research (Prevot et al., 2019). This work aims to investigate the physicochemical features of GL-II-73 to pick the best parenteral nanodelivery system for prospective research to assess its parameters. PB - Macedonian Pharmaceutical Association PB - Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy C3 - Macedonian Pharmaceutical Bulletin T1 - Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73 VL - 69 IS - Suppl 1 SP - 53 EP - 54 DO - 10.33320/maced.pharm.bull.2023.69.03.026 ER -
@conference{ author = "Đoković, Jelena and Marković, Bojan and Sharmin, Dishary and Cook, James M. and Savić, Miroslav and Savić, Snežana", year = "2023", abstract = "Nanopharmaceuticals offer a good option to avoid some of the difficulties that novel drug candidates confront. They can be tailored to adjust their water solubility, half-life, biodistribution, and govern the release of the integrated medication. Because of the excipients utilized, lipid nanocarriers (liposomes, nanoemulsions (NEs), nanoparticles) have been used to increase brain targeting (Bisso et al., 2020; Ilić et al., 2023). The investigated compound (GL-II-73) - (4R)-8- ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H- benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide is imidazobenzodiazepine (IBZD) ligand that acts as positive allosteric modulator on α-GABAA receptors and was shown to possess combined antidepressant and pro- cognitive effects, making it a promising candidate for further research (Prevot et al., 2019). This work aims to investigate the physicochemical features of GL-II-73 to pick the best parenteral nanodelivery system for prospective research to assess its parameters.", publisher = "Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy", journal = "Macedonian Pharmaceutical Bulletin", title = "Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73", volume = "69", number = "Suppl 1", pages = "53-54", doi = "10.33320/maced.pharm.bull.2023.69.03.026" }
Đoković, J., Marković, B., Sharmin, D., Cook, J. M., Savić, M.,& Savić, S.. (2023). Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73. in Macedonian Pharmaceutical Bulletin Macedonian Pharmaceutical Association., 69(Suppl 1), 53-54. https://doi.org/10.33320/maced.pharm.bull.2023.69.03.026
Đoković J, Marković B, Sharmin D, Cook JM, Savić M, Savić S. Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73. in Macedonian Pharmaceutical Bulletin. 2023;69(Suppl 1):53-54. doi:10.33320/maced.pharm.bull.2023.69.03.026 .
Đoković, Jelena, Marković, Bojan, Sharmin, Dishary, Cook, James M., Savić, Miroslav, Savić, Snežana, "Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73" in Macedonian Pharmaceutical Bulletin, 69, no. Suppl 1 (2023):53-54, https://doi.org/10.33320/maced.pharm.bull.2023.69.03.026 . .